NCT05451199招募中1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 154
- 试验地点
- 7
- 主要终点
- Incidence and severity of adverse events during treatment, and withdrawal from treatment due to adverse events
研究概览
简要总结
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily signed informed consent, and was able to communicate well with the investigator and can complete the study according to the study requirement.
- •Body mass index (BMI) between 18-26 kg/m2, the weight of male subject should not be less than 50 kg, and the weight of female subject should not be less than 45 kg.
- •The results of laboratory tests during the screening period are within the normal reference values of the population or study site;Or the results were slightly off but within acceptable limits, and the investigator evaluated that they were not clinically significant.
- •Fertility status: Female subjects who are infertile (i.e. physically unable to conceive, including postmenopausal or surgically infertile women);Male subjects and their partners must agree to use effective contraception for the entire study period and for 28 days after the last medication or for five half-lives, and male subjects shall not donate sperm during this period.
- •Male or female subjects aged ≥ 18 years and ≤ 65 years；
- •Diagnosis of plaque psoriasis；
- •All of the following 3 criteria are met at screening and randomization:
- •1）Psoriasis Area and Severity Index (PASI) ≥ 12; 2）Physician Global Assessment (PGA) ≥ 3; 3）Body surface area (BSA) affected by psoriasis ≥ 10%.
- •The subject is a candidate to receive systemic therapy and/or phototherapy.
排除标准
- •Unable to follow the study protocol requirements.
- •Evidence or history of clinically significant disease, or evidence or history of allergic disease.
- •Subjects with clinically significant gastrointestinal dysfunction that may affect drug intake, transport or absorption.
- •Acute disease state within 14 days before administration.
- •Currently or within 6 months prior to administration experiencing a severe infection or having a long-term or recurrent infection disease
- •Subjects and/or first-degree relatives have a genetic immune deficiency.
- •Major trauma or surgery within 3 months prior to the first administration.
- •Previous medical history of tuberculosis; The presence of investigator-judged signs or symptoms of active tuberculosis and the chest imaging showed active pulmonary tuberculosis at screening ；T-spoT test (T-SPOT) was positive at screening.
- •Urine drug test positive.
- •Subjects who have used tobacco/cigarettes or tobacco/cigarette products within 3 months prior to the first administration.
- •Subjects who donated more than 500 ml of blood (excluding plasma) within 56 days before the first dose, or planned to donate blood or blood components during the study period or within 1 month after the study finished.
- •Use of any other study drug specified in the protocol within 30 days prior to initial administration or within 5 half-lives(refer to whichever is longer).
- •Any traditional Chinese medicine (TCM) and over-the-counter (OTC) drugs, vitamins, systemic steroid hormone therapy, immunosuppressant or modulator therapy, hormone replacement therapy, and other food supplements or herbs were used 30 days before the first dose until follow-up visit.
- •Consume any food or drink containing caffeine within 48 hours prior your first administration.
- •Last use of stron , moderate and weak CYP1A2/CYP3A4 inhibitors or inducers less than 5 half-lives before the first dose of study drug, or planning to take medications, dietary supplements, or foods
- •Diet or dietary treatment within 30 days prior to initial administration or have significant change in eating habits.
- •Eat smoked charcoal fire foods (such as Carbon barbecue,etc) within 1 week prior to the study.
- •Any positive showed in the lab result of syphilis specific antibody, hepatitis C antibody (HCV-Ab), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or human immunodeficiency virus serological antibody (HIV-Ab) during screening.
- •Received vaccination with live virus vaccine, live attenuated vaccine or any live virus component is administered within 6 weeks prior to initial administration, or during the planned study period or within 8 weeks after the end of the study.
- •Non-plaque forms of psoriasis.
- •Drug-induced psoriasis.
- •Are taking or require oral or injectable corticosteroids for any medical condition.
- •Clinically significant test results at the time of screening that, in the investigator's judgment, may cause unacceptable risk to the participant.
- •History of active tuberculosis，active hepatitis B virus、active hepatitis C virus or Syphilis infection.
- •Clinically severe, progressive, or uncontrolled disease at screening； Pregnant female subjects.
- •breastfeeding female subjects.
- •Other situations judged by the investigator to be unsuitable to join this trial.
研究组 & 干预措施
ICP-488
Experimental
Single ascending doses of ICP-488 tablet; Multiple ascending doses of ICP-488 tablet; Part3 Patients with Psoriasis:ICP-488 tablet.
干预措施: ICP-488 (Drug)
Placebo
Placebo Comparator
Single ascending doses of placebo; Multiple ascending doses of placebo; Part3 Patients with Psoriasis of placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence and severity of adverse events during treatment, and withdrawal from treatment due to adverse events
时间窗: Single ascending dose: 1day；Multiple ascending dose: 28 days
次要结局
- Static Physician's Global Assessment （sPGA）(Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56)
- Peak Pruritus Numerical Rating Scale （PP-NRS）(Day1-Day14, Day21, Day28, Day35, Day42, Day56)
- Cmax(Single ascending dose: 1day；Multiple ascending dose: 28 days)
- Dermatology quality of life index （DLQI）(Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56)
- Body Surface Area （BSA）(Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56)
- Psoriasis Area and Severity Index （PASI）(Day1,Day7,Day14,Day21,Day28,Day35,Day42,Day56)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy SubjectsHealthy SubjectsNCT05399030Beijing InnoCare Pharma Tech Co., Ltd.72
已完成
1 期
A Multiple Ascending Dose Study of KBP-7072 in Healthy SubjectsHealthyNCT02654626KBP Biosciences16
已完成
1 期
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy SubjectsHealthy SubjectsNCT02099201Idorsia Pharmaceuticals Ltd.65
已完成
3 期
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® GelAcne VulgarisNCT02005666Zydus Lifesciences Limited850
已完成
2 期
Phase 2a Study of HPG1860 in Subjects With NASHNASH - Nonalcoholic SteatohepatitisNCT05338034Hepagene (Shanghai) Co., Ltd.89